Repurposing ivacaftor to attenuate LPS-induced acute lung injury: evidence from a non-cystic fibrosis model

Abstract

In this study, we explicitly evaluate the anti-inflammatory effects of ivacaftor as a route-of-delivery comparison (intraperitoneal vs. intratracheal) in a reproducible LPS-induced lung inflammation model. We evaluated the effects of ivacaftor [40 mg/kg, administered either intraperitoneally (IP) or intratracheally (IT)] on lipopolysaccharide (LPS, 8 μg)-induced lung inflammation in 8–10-week-old female C57BL/6 mice. Mice were euthanised at 24 or 72 h post-treatment, and serum, bronchoalveolar lavage fluid (BALF), and lung tissue were collected for analysis. Inflammation was assessed by measuring immune cell infiltration, fluorescence-activated cell sorting (FACS)-based leucocyte profiling, ..